After Letter to Commissioner, FDA Finally Gives Vanda Reason for Rejection, Chance for Hearing

After a series of strongly worded letters—one of which was addressed directly to Commissioner Robert Califf—the FDA has publicly laid out its reasoning for rejecting Vanda Pharmaceuticals’ gastroparesis drug candidate tradipitant.